| AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent viral diseases. Co.'s key product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. ALVR106 is Co.'s second multi-virus-targeted off-the-shelf VST product candidate that it developed to target respiratory diseases. ALVR109 is an allogeneic, off-the-shelf single virus-targeted cell therapy designed to target SARS-CoV-2. Co. is also developing ALVR107 designed to target hepatitis B, or HBV, infected cells and treat chronic HBV infections and ALVR108 to treat human herpesvirus-8. We show 5 historical shares outstanding datapoints in our ALVR shares outstanding history coverage, used to compute ALVR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALVR market cap history over the course of time is important for investors
interested in comparing ALVR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALVR versus a peer is one thing; comparing
ALVR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALVR can fluctuate over the course of history.
With this page we aim to empower investors researching ALVR by allowing them to research the ALVR market cap history.